Health
Dartmouth TB vaccine moves one step closer to a full Phase 3 efficacy trial – News-Medical.Net
Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth’s Geisel School of Medicine and publi…
Reviewed by Emily Henderson, B.Sc.Sep 29 2020
Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth’s Geisel School of Medicine and published in the journal Vaccine. The three-year trial was conducted among 650 adolescents in Tanzania, a nation with high rates of TB infection, and showed that the vaccine was safe and induced immune responses against the disease.
Tuberculosis is most common infectious disease cause of death in…
-
Noosa News18 hours agoIncrease in extreme weather events poses ‘substantial risk’ to blood supplies, researchers warn
-
General22 hours agoGerman palliative care doctor with alleged ‘lust for murder’ accused of killing 15 patients
-
Noosa News8 hours agoAustralians tell ABC’s Your Say how they saw the second leaders debate
-
Noosa News13 hours agoManjimup engineer turns previously wasted avocados into liquid gold